We are dedicated to finding better ways to diagnose and treat frontotemporal dementia, alongside working to discover the cause of the condition.
Frontier is a highly collaborative, interdisciplinary research clinic that investigates frontotemporal dementia (FTD) in collaboration with ForeFront Ageing and Neurodegeneration. FTD is Australia’s second most common degenerative disease that causes dementia in younger adults. As the first ever research group to concentrate on FTD in Australia, Frontier is dedicated to identifying better ways to diagnose FTD, finding the cause and developing effective treatments for the condition.
Our multidisciplinary research examines the neurological, psychological and biological brain function in FTD, as well as how the disease impacts on the lives of patients and their families. Our team is currently investigating:
Are you a patient living with FTD? Help us find a cure – get involved in our research.
Additional resources for carers can be found here.
Help us impact the lives of people affected by frontotemporal dementia. With your support, our research can make a real difference. We welcome any gift, large or small, so make a donation today.
We have developed a range of tests to help clinicians accurately assess cognitive function and diagnose frontotemporal dementia in patients, such as the ACE-III and the Frontier Executive Screen test. Access the tests here.
Guidelines for the remote administration of the Addenbrooke's Cognitive Examination-III (ACE-III) test are now available. Version A of the Australian and UK forms have also been adapted and available here.
If you would like to know when these tests are updated or changed, please email us so we can keep you informed.